Ensysce Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-10.2M | $-8.0M | $-10.6M | $-24.2M | $-29.1M | $4.3M | $-1.1M | $2.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $6.5K | $0 | $0 | $0 | $151 | $201 | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $177.1K | $110.7K | $879.2K | $1.1M | $121.8K | $178.7K | — | — |
| Net Cash from Operating Activities | $-7.8M | $-7.5M | $-10.8M | $-17.9M | $-8.2M | $-1.2M | $-1.4M | $-1.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $123.6K | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-123.6K | — | — | $4.5K | — | $183.4M | $11.9M | $838.6K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | $184.8M | $11.6M | — |
| Net Cash from Financing Activities | $8.7M | $9.9M | $8.8M | $8.8M | $20.3M | $1.1M | $-11.0M | $-32.0K |
| Net Change in Cash | $808.3K | $2.4M | $-2.0M | $-9.1M | $12.1M | $-1.0M | $-597.2K | $-431.7K |
| Free Cash Flow | $-7.9M | — | — | — | — | — | — | — |